Transverse Medical is an early-stage medical device company focused on the POINT-GUARD™ Cerebral Embolic Protection (CEP) device for use during transcatheter procedures such as TAVR to prevent embolic particles from reaching the brain. The Point-Guard platform is designed to provide full brain protection, accommodate variable arch anatomies, and offer operator ease of use and aortic arch stabilization. The POINT-GUARD device is currently in a Feasibility Clinical Study at Victorian Heart Hospital in Melbourne, Australia under the TGA Clinical Trial Notification scheme and has not been approved for human use by the US FDA. Proceeds from the recent financing will support continuation of clinical validation in Australia and ongoing development of the Point-Guard platform. The company plans to expand operational infrastructure and grow engineering, regulatory, quality, and operating teams as it advances toward pivotal trials and an FDA IDE submission.

Total raised

$10M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2025